Nat Commun: The VEGF-like vaccine showed initial efficacy in neurofibromatosis type 2.

Anti-VEGF antibody beva bead monoantigen is effective in the treatment of neurofibromatosis type 2 (NF2).
theory, vascular endotrative growth factor subjectors (VEGFRs) specific cytotoxic T lymphocytes (CTLs) can kill tumor vascular cells and tumor cells that express VEGFRs.
, we presented exploratory clinical studies of the VEGFRs peptide vaccine in 7 patients with progressive NF2-based schizophrenic tumors, the results of which were published online in Nat Commun.
2/5 of patients (40%) who were assessed according to international guidelines had improved hearing, while word recognition scores had increased.
20 percent reduction in tumor volume was observed in≥ 2 patients, including 1 patient with beval monoantin.
no serious adverse events associated with vaccines have occurred.
VEGFR1 specificity and VEGFR2 specific CTL were induced in 6 patients.
after two patients were vaccinated, VEGFRs were observed to show a significant decrease in expression in the split tumor.
, the clinical immunotherapy study demonstrated the safety and initial efficacy of VEGFRs peptide vaccination in NF2 patients.
.